Pillar Pacific Capital Management LLC Acquires 1675 Shares of Incyte Corporation (INCY)

Paterniano Del Favero
Agosto 4, 2017

Mn Services Vermogensbeheer B.V. raised its stake in Incyte Corporation (NASDAQ:INCY) by 511.5% during the second quarter, according to its most recent filing with the SEC. Institutional investors and hedge funds own 92.33% of the company's stock.

Several other institutional investors have also recently modified their holdings of INCY. Tower Research Capital LLC TRC acquired a new position in Incyte Corporation during the first quarter worth $105,000. State Street Corp now owns 7,581,684 shares of the biopharmaceutical company's stock worth $1,013,437,000 after buying an additional 3,983,207 shares during the period. Vanguard Group Inc. now owns 15,415,857 shares of the biopharmaceutical company's stock worth $2,060,638,000 after buying an additional 2,847,907 shares during the period. Finally, UBS Asset Management Americas Inc. raised its position in shares of Incyte Corporation by 23.9% in the first quarter. Teachers Advisors LLC increased its position in Incyte Corporation by 6.5% in the fourth quarter. FNY Partners Fund LP now owns 985 shares of the biopharmaceutical company's stock valued at $131,000 after buying an additional 965 shares in the last quarter.

The share price of Incyte Corporation (NASDAQ:INCY) was down -3.40% during the last trading session, with a day high of 134.94. The fund owned 10,500 shares of the biopharmaceutical company's stock after selling 300 shares during the period. Moreover, Bessemer Gru has 0% invested in Incyte Corporation (NASDAQ:INCY) for 47 shares. It has ranged in price between $124.095-$128.55 after having started the session at $128.5 as compared to the previous trading day's close of $128.76. Incyte Corp now has $25.61 billion valuation. Incyte Corporation has a 12-month low of $75.52 and a 12-month high of $153.15.

The stock's 50 day moving average is 130.23 and its 200 day moving average is 129.04.

In the last earnings report the EPS was $-0.56 and is expected to be $-0.74 for the current year with 204,774,000 shares presently outstanding. The company had revenue of $326.40 million for the quarter, compared to analyst estimates of $318.45 million. Incyte Corporation had a negative net margin of 8.72% and a negative return on equity of 20.09%. The firm's quarterly revenue was up 32.5% compared to the same quarter past year. During the same quarter in the prior year, the company posted $0.12 EPS. Equities research analysts expect that Incyte Corporation will post ($0.74) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: "APG Asset Management N.V. Cuts Stake in Incyte Corporation (NASDAQ:INCY)" was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this news story on another publication, it was stolen and reposted in violation of US & global copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/03/incyte-corporation-incy-shares-bought-by-grandfield-dodd-llc.html.

BMO Capital Markets reissued their buy rating on shares of Incyte Corporation (NASDAQ:INCY) in a research report sent to investors on Friday, July 21st. Raymond James Financial, Inc. lowered shares of Incyte Corporation from an "outperform" rating to a "hold" rating in a research report on Thursday, April 6th. They set a "buy" rating and a $185.00 price target for the company. (The) dropped their target price on shares of Incyte Corporation from $149.00 to $136.00 and set a buy rating for the company in a research report on Tuesday, April 18th. Zacks Investment Research upgraded shares of Incyte Corporation from a sell rating to a hold rating in a research note on Tuesday, May 23rd. October 5 investment analysts at Jefferies maintained a company rating of "Hold" and moved up the price target to $109.00 from $106.00. The company now has an average rating of "Buy" and a consensus target price of $140.39. 8,577 shares were sold by Huber Reid M, worth $1.02 million on Friday, May 5. Following the sale, the executive vice president now owns 19,356 shares in the company, valued at approximately $2,537,378.04. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. $4.41 million worth of Incyte Corporation (NASDAQ:INCY) shares were sold by Stein Steven H. Siegel Eric H. sold $227,009 worth of Incyte Corporation (NASDAQ:INCY) on Monday, May 1. The shares were sold at an average price of $124.73, for a total transaction of $227,008.60. Corporate insiders own 17.70% of the company's stock. The disclosure for this purchase can be found here. Insiders sold 51,940 shares of company stock worth $6,381,746 in the last quarter.

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. The Business's portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Want to see what other hedge funds are holding INCY?

Altre relazioni OverNewsmagazine

Discuti questo articolo